NTRA
HealthcareNatera, Inc. · Medical - Diagnostics & Research · $29B
What is Natera, Inc.?
Natera is a molecular diagnostics company focused on genetic testing across prenatal care, oncology, and organ transplant monitoring. Its tests are delivered through a direct sales force and a broad network of laboratory partners worldwide.
Natera develops and commercializes cell-free DNA testing services. Revenue comes from genetic screening tests ordered by clinicians and processed through Natera's laboratories or licensed to partner labs via its cloud-based bioinformatics platform. The company serves patients across reproductive health, cancer surveillance, and transplant medicine.
Founded in 2015 and headquartered in Austin, US.
- Panorama non-invasive prenatal screening
- Signatera circulating tumor DNA test
- Prospera organ transplant rejection assessment
- Constellation cloud-based bioinformatics platform
Is NTRA a Good Stock to Buy?
UQS Score rates NTRA as Below Average overall.
Natera's Growth pillar stands out as Strong, reflecting rapid expansion of its test volumes and addressable markets across prenatal, oncology, and transplant categories. Risk is rated Neutral, suggesting the business is not in acute financial distress.
Quality and Moat are both rated Weak, pointing to profitability challenges and limited durable competitive advantages. Valuation is Elevated, meaning the current price already reflects considerable optimism.
See the exact pillar breakdown and full financial metrics by signing up for a Pro membership at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NTRA pay dividends?
No — Natera, Inc. does not currently pay a dividend.
Natera does not pay a dividend. As a growth-stage diagnostics company still investing heavily in expanding its test menu and commercial infrastructure, available capital is directed toward research, sales growth, and market penetration rather than shareholder distributions.
When does NTRA report earnings?
Natera reports earnings on a quarterly cadence, consistent with US-listed public companies.
Revenue growth has been a consistent theme in recent quarters, driven by rising test volumes across its core product lines. However, profitability remains a work in progress, which is reflected in the Weak Quality pillar rating.
For the most recent quarter's results, visit Natera's investor relations page directly.
NTRA Price History
+118.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Natera, Inc.?
Based on Natera, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Natera do?
Natera develops molecular genetic tests used in prenatal screening, cancer detection, and organ transplant monitoring. Its tests analyze cell-free DNA from blood samples and are offered through clinicians, hospitals, and laboratory partners globally.
Does NTRA pay dividends?
No, Natera does not currently pay a dividend. The company reinvests available resources into expanding its testing capabilities, growing its commercial footprint, and funding ongoing research and development.
When does NTRA report earnings?
Natera follows a standard quarterly reporting schedule. Specific upcoming dates are not covered by our data source — check Natera's investor relations page for the current earnings calendar.
Is NTRA a good stock to buy?
UQS Score rates NTRA as Below Average. While Growth is Strong, both Quality and Moat are Weak, and Valuation is Elevated. Investors should weigh the growth trajectory against profitability concerns and current pricing before making any decision.
Is NTRA overvalued?
The UQS Valuation pillar for NTRA is rated Elevated, suggesting the market price reflects high expectations for future growth. Whether that premium is justified depends on how the company's profitability trajectory develops over time.
What is NTRA's market cap bracket?
Natera is classified as a large-cap stock, placing it among the larger publicly traded companies in the diagnostics and genomics space.
Is NTRA a long-term quality investment?
From a quality indicator perspective, NTRA's profile is mixed. Strong Growth is a positive long-term signal, but Weak Quality and Moat ratings suggest the business has not yet demonstrated durable profitability or a clearly defensible competitive position. Pro members can view the complete analysis.
What sector does NTRA belong to?
Natera operates in the Healthcare sector, specifically within molecular diagnostics and genetic testing — a segment that intersects genomics technology with clinical laboratory services.
Unlock Full NTRA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access full financial metrics and trend data
- ✓Compare NTRA against sector peers on quality and valuation
- ✓Get the complete analyst-style breakdown available to Pro members
Pro Analysis
NTRA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | 37.2 | 17.4 | 38.0 | 81.6 | 47.1 | 0.0 | — |
NTRA — Pillar Breakdown
Quality
— 17.3/100 (25%)Natera, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 81.6/100 (20%)Natera, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 46.7/100 (15%)Natera, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Natera, Inc. appears expensively valued relative to its fundamentals and growth prospects.
How many years of FCF the market cap represents.
Moat
— 38/100 (25%)Natera, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NTRA.
Score Composition
Financial Data
More Stock Analysis
How is the NTRA UQS Score Calculated?
The UQS (Unified Quality Score) for Natera, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Natera, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Natera, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.